Trial Profile
Phase Ib Study of BKM120 Combined With Abiraterone Acetate for Docetaxel-pretreated, Castrate-resistant, Metastatic Prostate Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Buparlisib (Primary) ; Abiraterone acetate; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions
- 25 Jan 2017 Planned primary completion date changed from 1 Nov 2016 to 1 Sep 2017.
- 25 Jan 2016 Status changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov.
- 14 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.